May 27 | Bio-IT World | Biotech funding must be hot indeed when an 18-month-old immunotherapy company can pledge hundreds of millions to an 18-month-old genome editing company, but there's plenty of promise combining CAR T therapy with CRISPR technology — as rivals Novartis and Intellia Therapeutics made clear when they forged their own partnership this January.
May 27 | Bio-IT World News Brief | Yesterday afternoon QIAGEN announced the commercial launch of QIAGEN Clinical Insight (QCI), a bioinformatics content and software platform for clinical testing labs to interpret and report on genomic variants identified in next-generation sequencing (NGS). The first two supported applications for the bioinformatics platform are in oncology, for somatic and hereditary cancer testing.
May 21 | Clinical Informatics News | Boston Children’s Hospital is launching CLARITY Undiagnosed, a $25,000 competition to identify molecular diagnoses for five families with as-yet undiagnosed conditions. The Challenge kicks off in conjunction with a documentary film tracing the journeys of the patients and—possibly—the teams. Teams have until June 11 to register
May 21 | Bio-IT World | As the Genome in a Bottle Consortium and the National Institute of Standards and Technology announce the first reference DNA samples as trusted standards for genomic sequencing, the FDA weighs a regulatory role for the new reference material.
May 20 | Bio-IT World | The Lieber Institute for Brain Development (LIBD) announced a 5-year, $10.5 million grant from the National Institutes of Health (NIH) to support a first-of-its-kind multi-site, interdisciplinary project to research potentially non-inherited genetic causes of schizophrenia. By identifying the root biological origins now, more precise and effective therapies can be developed later.
May 20 | Xconomy | Under a collaboration announced today,
San Diego-based Cypher Genomics said it would use its biomarker
discovery service to help New Jersey's Celgene identify key genetic
variants among patients who respond well to specific drugs.
May 19 | Computerworld | Amazon Web Services is hoping
better management tools will convince enterprises to move more
applications to the cloud, but getting their internal management
processes right is even more important than anything the vendor can
May 19 | Bio-IT World | Robert Gentleman’s goal is to “bring bioinformatics and computational drug discovery to complement the really strong genetics” already at 23andMe. He spoke with Bio-IT World about open science at a for-profit venture, the challenges of drug discovery, and what’s left to find via SNP chips.
May 19 | Xconomy | One of gene therapy's major unanswered
questions is just what it'll take to convince U.S. regulators to
approve one of these treatments.
May 18 | MIT Technology Review | With new tools to isolate
individual cells and profile their genetic signatures, researchers
are undertaking a microscopic quest to find out what we're really
May 15 | Bio-IT World | The Michael J. Fox Foundation, dedicated to driving basic research in Parkinson's disease, received a special Judges' Prize at this year's Bio-IT World Best Practices Awards for its work implementing the tranSMART platform for data sharing and analysis, including innovative programs like a patient registry and integration with studies of other neurodegenerative diseases.
May 14 | Xconomy | With the Allen Cell Types Database, the
Allen Institute for Brain Science aims to catalog and classify the
types of neurons that fill the brain.
May 14 | Bio-IT World | Clive Brown’s Oxford Nanopore took over our Twitter feed on Thursday afternoon with news coming out of the London Calling event (#nanoporeconf). Many in attendance (and watching the Twitter feed) called the announcements “game-changing” and likened the atmosphere to Apple’s iPhone announcement in 2007.
May 14 | Bio-IT World News Brief | Mayo Clinic in Rochester, Minn., has announced plans to sequence genes from 10,000 patients for genetic variants that could affect their responses to a variety of medications, as part of a study that will track the long-term health outcomes of patients who undergo pharmacogenetic testing.
May 14 | Forbes | Three former top researchers at
Genentech, the legendary biotech that is now part of Roche Holding,
have raised $217 million in venture capital to start a new company,
Denali Therapeutics, focused on treating and curing
neurodegenerative diseases like Alzheimer's, ALS, and Parkinson's.
May 13 | Bio-IT World | To understand how neural circuits give rise to complex mental phenomena, neuroscientists need detailed maps of brain cells in their natural environment. With an online game called EyeWire, one group of researchers is enlisting thousands of ordinary people to do what the best artificial intelligence cannot: turn huge numbers of electron microscope images of the retina into accurate, three-dimensional models of neurons as they appear in living tissue.
May 12 | Bio-IT World | Cleversafe, a private cloud platform, announced today that it has joined the iRODS Consortium, a membership-based foundation organized to sustain the integrated Rule-Oriented Data System (iRODS) as free open source data management software.
May 11 | New York Times | The biochemist at the University
of California, Berkeley, helped make a monumental discovery: a
relatively simple way to alter any organism's DNA. But she is stuck
in a patent fight over it.
May 07 | Bio-IT World | CHI’s Clinical Genome Conference (TCGC) always offers a packed schedule of talks at the cutting edge of medical genomics. With a program once again pushing the envelope of where genomics and medicine will take us in the coming year, we aren’t expecting much down time over the three event days, though we always work in at least one trip out of San Francisco’s Japantown for Burmese tea leaf salad. Here’s what else we are looking forward to on the TCGC menu.
May 06 | MIT Technology Review | Apple is collaborating
with U.S. researchers to launch apps that would offer some iPhone
owners the chance to get their DNA tested, many of them for the
first time, according to people familiar with the plans. The apps
are based on ResearchKit.